News & Events

New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium

Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.  The data are derived from GeneCentric’s expertise in the identification of RNA-based Predictive Response Signatures and through collaborations with researchers at leading institutions and pharmaceutical companies.  First to be presented is a real-world pooled analysis of patients with metastatic, muscle invasive bladder cancer (MIBC), derived from the ongoing collaboration with researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center and Janssen Research & Development, LLC.  The predictive value of fibroblast growth factor (FGFR) alterations on the treatment outcome of MIBC patients treated with immune checkpoint blockade (Anti-PD-L1/Anti-PD-1) was evaluated in the current analysis.

“With the recent targeted therapy advances for patients with MIBC, including FGFR inhibition, it is essential that new molecular diagnostic tools ensure the right treatments are delivered to the right patients to maximize clinical outcomes,” said Dr. Mike Milburn, President and CEO of GeneCentric Therapeutics.  “We look forward to our continued collaborations with key academic and pharmaceutical collaborators to achieve this goal.”

In another presentation, GeneCentric and their strategic laboratory services provider, OmniSeq, will provide initial results from an ongoing collaboration on molecular characterization of advanced MIBC samples where a new, low-input targeted RNAseq approach requiring 1/20th of the RNA normally required for next-generation sequencing and gene-expression analysis was demonstrated.

“We are excited to see the further evolution of targeted RNAseq strategies where cancer patients with limited tumor specimens may have the opportunity to still benefit from the recent advances with RNA-based molecular characterization,” said Jeffrey Conroy, Chief Scientific Officer of OmniSeq.

Copies of both presentations will be available following the meeting at

Details of the presentations are as follows:

Title: “Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data.”
Abstract Number: 493

Date:  February 14, 2020
Time:  12:15 to 1:45 PM and 5:15 to 6:15 PM
First Author: William Kim, MD, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Title: “Molecular characterization of advanced muscle invasive bladder cancer (MIBC): Comparison of low-input targeted RNA sequencing (RNAseq) strategies.”
Abstract Number: 564

Date:  February 14, 2020
Time:  12:15 to 1:45 PM and 5:15 to 6:15 PM
First Author: Yoichiro Shibata, PhD, Senior Bioinformatics Scientist, GeneCentric Therapeutics

About GeneCentric
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider.  The company’s technologies are designed to parse the complexity of tumor and immune biology to discover and develop signatures of responder populations to oncology drugs.  GeneCentric is commercializing its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout pre-clinical testing, clinical drug development and commercialization lifecycle phases.  In addition to bladder cancer, GeneCentric has gene expression-based Cancer Profilers for lung, head and neck, pancreatic, kidney, glioblastoma, melanoma and multiple myeloma, as well as signatures to characterize therapeutic cancer targets such as PD(L)-1, PARP, FGFR2/3, and specific cytokines.  For more information, please visit